Tag: Keytruda

According to data from 2024, Merck's cancer drug Keytruda has claimed the top spot in global pharmaceutical sales, showcasing a significant shift in the market after years of AbbVie's Humira leading the pack. For those asking, 'What is the top selling drug in America?', the answer has become more complex, reflecting major changes driven by biosimilar competition, new drug classes, and shifting patient needs.

With global sales reaching nearly $29.5 billion in 2024, Merck's Keytruda has firmly held its position as the top earner in the pharmaceutical industry, making it the answer to the question: **What is the highest selling drug in the world?**. This cancer immunotherapy's continued success showcases the immense market power of advanced oncology treatments, especially as older blockbusters face new market dynamics.

In 2024, the global pharmaceutical market saw the top 50 best-selling drugs generate over $116 billion in revenue. Answering the question, 'What are the top 3 drugs used worldwide?', requires clarity, as the most widely used medicines by volume (often cheap generics) differ significantly from the most profitable ones by sales revenue. Based on 2024 revenue, the pharmaceutical market's top three blockbuster drugs are Merck's Keytruda, Novo Nordisk's Ozempic, and Bristol Myers Squibb/Pfizer's Eliquis.

First approved by the FDA in 2014 for treating metastatic melanoma, the cancer immunotherapy drug Keytruda is one of the world's best-selling medicines. For patients and healthcare professionals, understanding which pharma company makes KEYTRUDA is important for tracing its origins and development. The answer is the pharmaceutical giant Merck & Co., Inc., also known as MSD outside the United States and Canada.

For over a decade, Humira (adalimumab) dominated the pharmaceutical market, achieving peak annual sales of more than $20 billion, but its reign is over. Determining which is the most successful biologic drug requires examining metrics beyond just peak sales, considering factors like clinical impact, therapeutic area, and market longevity. This article explores the biggest names in biologics, comparing historical and recent successes.

With 5-year overall survival rates for certain non-small cell lung cancer patients reaching as high as 29.6% with its use [1.10.4], it is essential to understand the answer to the question, **what class of drug is pembrolizumab?**

AbbVie's Humira has generated approximately $240 billion in revenue since its launch, making it the highest-grossing drug of all time [1.4.3]. However, the title of 'fastest-selling' is more complex, pitting launch speed against total lifetime sales.

With sales reaching nearly $29.5 billion in 2024, Merck's cancer therapy Keytruda has affirmed its position as the top-selling drug globally [1.2.1, 1.2.2]. This article answers the question: **What is the most selling drug in the world?** and examines the forces driving its success.

Based on 10-year follow-up data for metastatic melanoma, 34% of patients treated with Keytruda were still alive, demonstrating a sustained overall survival benefit. The length of time Keytruda can extend life depends heavily on various factors, including the type of cancer, its stage, and the patient's individual response to the immunotherapy.

In 2019, over 112 million prescriptions were written for Atorvastatin, making it one of the most prescribed drugs in the US [1.3.1]. When asking, 'What are the big 3 drugs?', the answer depends entirely on the metric: sales, prescription volume, or historical importance.